Table 2 Meta-analysis of CD155 expression and prognosis in cancers

OS

26 (4325)

1.772 (1.441–2.178)

84.5

< 0.001

5.42

< 0.001

 Digestive system cancer

11 (1719)

1.570 (1.120–2.201)

87.9

< 0.001

2.62

0.009

 Hepatobiliary pancreatic cancer

7 (1014)

1.677 (1.037–2.712)

90.0

< 0.001

2.11

0.035

 Digestive tract cancer

4 (705)

1.512 (1.016–2.250)

51.7

0.054

2.04

0.042

 Breast cancer

4 (600)

2.137 (1.448–3.154)

0.0

0.497

3.82

< 0.001

 Lung cancer

4 (749)

1.706 (1.193–2.440)

58.8

0.063

2.93

0.003

 Head and neck cancer

2 (490)

1.470 (1.160–1.862)

0.0

0.623

3.19

0.001

 Others^a

5 (767)

2.150 (1.348–3.428)

63.2

0.028

3.22

0.001

 Multivariate analysis

15 (2743)

1.635 (1.319–2.027)

61.3

0.001

4.48

< 0.001

 Univariate analysis

21 (3403)

1.792 (1.404–2.288)

88.0

< 0.001

4.69

< 0.001

 ≥ 3 years

13 (1950)

1.568 (1.127–2.183)

86.6

< 0.001

2.67

0.008

 < 3 years

13 (2375)

1.805 (1.493–2.182)

48.2

0.026

6.10

< 0.001

 < 200

18 (1943)

1.839 (1.357–2.494)

85.3

< 0.001

3.92

< 0.001

 > 200

8 (2382)

1.603 (1.365–1.881)

31.9

0.173

5.76

< 0.001

 IHC

20 (3373)

1.863 (1.470–2.363)

86.7

< 0.001

5.14

< 0.001

 Others

6 (952)

1.519 (1.046–2.205)

49.8

0.077

2.20

0.028

 Asian

22 (3604)

1.714 (1.369–2.146)

85.2

< 0.001

4.70

< 0.001

 Europe

4 (721)

1.976 (1.411–2.769)

27.3

0.248

3.96

< 0.001